In conclusion, our study suggested that CD73 expression is an important prognostic factor in patients with ESCC, with higher CD73 expression seen after treatment with neoadjuvant chemotherapy or CRT. The gene discussed is NT5E; the disease is esophageal squamous cell carcinoma.